pharma · Chronic Spontaneous Urticaria (CSU) · Asthma · SPRY
Ars Pharmaceuticals Irl Limited
Ars Pharmaceuticals Irl drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ars Pharmaceuticals Irl drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antiinfectives for systemic use (J07) compound in Ars Pharmaceuticals Irl's portfolio. Mechanism: Biological vaccine - induces immune response.
Various (V09) compound in Ars Pharmaceuticals Irl's portfolio.
US regulatory status: approved. Molecular target: Adrenergic receptor.
US regulatory status: approved. Mechanism: Diagnostic agent.
Development asset linked to Ars Pharmaceuticals Irl in public FDA and regional records.
Development asset linked to Ars Pharmaceuticals Irl in public FDA and regional records.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.